TheraRadar

Pharma Intelligence, Simplified

Data updated: Mar 10, 2026

METHSCOPOLAMINE BROMIDE

METHSCOPOLAMINE BROMIDE
Gastroenterology Approved 1976-10-18
5
Indications
--
Phase 3 Trials
49
Years on Market

Details

Status
Prescription
First Approved
1976-10-18
Routes
ORAL
Dosage Forms
TABLET

METHSCOPOLAMINE BROMIDE Approval History

Loading approval history...

What METHSCOPOLAMINE BROMIDE Treats

1 indications

METHSCOPOLAMINE BROMIDE is approved for 1 conditions since its original approval in 1976. These indications span multiple therapeutic areas including oncology, immunology, and more.

  • Peptic Ulcer
Source: FDA Label
๐Ÿ”ฌ

Active Pipeline

Pro

Ongoing clinical trials by development phase

Loading...
โญ

Key Completed Trials

Pro

Completed studies with published results, ranked by significance

Loading...
๐Ÿ“Š

Trial Timeline

Full development history with FDA approval milestones

Loading...
Understanding FDA Approval Types
Count Type What it means
- ORIG Original approval - drug first enters market
- SUPPL - Efficacy New indication (new disease/condition approved)
- SUPPL - Labeling Label text changes (warnings, dosing updates)
- SUPPL - Manufacturing Production changes (new facility)
- SUPPL - Chemistry Formulation changes (new dosage strength)

Green lines in the timeline show ORIG and Efficacy approvals - the clinically meaningful milestones.

METHSCOPOLAMINE BROMIDE FDA Label Details

Pro

Indications & Usage

Adjunctive therapy for the treatment of peptic ulcer. METHSCOPOLAMINE BROMIDE HAS NOT BEEN SHOWN TO BE EFFECTIVE IN CONTRIBUTING TO THE HEALING OF PEPTIC ULCER, DECREASING THE RATE OF RECURRENCE OR PREVENTING COMPLICATIONS.

Want competitive intelligence?

See who's developing similar drugs and track their progress

View Pipeline Dashboard

Data Sources

Data sourced from official FDA and NIH databases. Click links to verify on original sources.